Author: Allen Veak

SARASOTA, Fla., December 4, 2017 - Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies following pre-IND written communications with the U.S. Food and Drug Administration (FDA). Nu-8 will...

SARASOTA, Fla., Sept. 27, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced it will present at the BioPharm America Conference top-line Phase 1/2a clinical data for its lead program, topically applied Nu-3 antimicrobial, to eliminate infection and promote wound healing in patients...

SARASOTA, Fla., Aug. 31, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that Neil J. Campbell, MA, MBA, and Leonard DeRoma, MBA, will be joining the company's Board of Directors. Mr. Campbell has over 25 years as a global C-level serial entrepreneur executive,...